<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:16:13Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8483468" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8483468</identifier>
        <datestamp>2021-10-06</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah36206" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8483468</article-id>
              <article-id pub-id-type="pmcid">PMC8483468</article-id>
              <article-id pub-id-type="pmc-uid">8483468</article-id>
              <article-id pub-id-type="pmid">34227397</article-id>
              <article-id pub-id-type="pmid">34227397</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.120.019017</article-id>
              <article-id pub-id-type="publisher-id">JAH36206</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>One‐Year Landmark Analysis of the Effect of Beta‐Blocker Dose on Survival After Acute Myocardial Infarction</article-title>
                <alt-title alt-title-type="right-running-head">Beta‐Blockers After MI</alt-title>
                <alt-title alt-title-type="left-running-head">Goldberger et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah36206-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Goldberger</surname>
                    <given-names>Jeffrey J.</given-names>
                  </name>
                  <degrees>MD, MBA</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9802-1851</contrib-id>
                  <xref rid="jah36206-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>j-goldberger@miami.edu</email>
                  </address>
                </contrib>
                <contrib id="jah36206-cr-0002" contrib-type="author">
                  <name>
                    <surname>Subačius</surname>
                    <given-names>Haris</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref rid="jah36206-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah36206-cr-0003" contrib-type="author">
                  <name>
                    <surname>Marroquin</surname>
                    <given-names>Oscar C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36206-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah36206-cr-0004" contrib-type="author">
                  <name>
                    <surname>Beau</surname>
                    <given-names>Scott L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36206-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah36206-cr-0005" contrib-type="author">
                  <name>
                    <surname>Simonson</surname>
                    <given-names>Jay</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36206-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36206-cr-0006" contrib-type="author">
                  <collab collab-type="authors">OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) Investigators<contrib-group><contrib id="jah36206-cr-0007" contrib-type="author"><name><surname>Desai</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0008" contrib-type="author"><name><surname>Betzen</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0009" contrib-type="author"><name><surname>DeLuna</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0010" contrib-type="author"><name><surname>Whitehill</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0011" contrib-type="author"><name><surname>Hatch</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0012" contrib-type="author"><name><surname>Janak</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0013" contrib-type="author"><name><surname>Cherry</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0014" contrib-type="author"><name><surname>Gonzalez</surname><given-names>E.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0015" contrib-type="author"><name><surname>Cruz</surname><given-names>I.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0016" contrib-type="author"><name><surname>Johnson</surname><given-names>E.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0017" contrib-type="author"><name><surname>Allbritton</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0018" contrib-type="author"><name><surname>Derrick</surname><given-names>V.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0019" contrib-type="author"><name><surname>Fishman</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0020" contrib-type="author"><name><surname>Assalone</surname><given-names>V.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0021" contrib-type="author"><name><surname>Mahon</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0022" contrib-type="author"><name><surname>Lustgarten</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0023" contrib-type="author"><name><surname>Rowen</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0024" contrib-type="author"><name><surname>Bessette</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0025" contrib-type="author"><name><surname>Alemy</surname><given-names>B.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0026" contrib-type="author"><name><surname>Dan</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0027" contrib-type="author"><name><surname>Picardi</surname><given-names>K.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0028" contrib-type="author"><name><surname>Schuger</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0029" contrib-type="author"><name><surname>Dzidowski</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0030" contrib-type="author"><name><surname>McCarthy</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0031" contrib-type="author"><name><surname>Fields</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0032" contrib-type="author"><name><surname>Alexander</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0033" contrib-type="author"><name><surname>Nair</surname><given-names>G.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0034" contrib-type="author"><name><surname>Kovacs</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0035" contrib-type="author"><name><surname>Beasley</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0036" contrib-type="author"><name><surname>Strickland</surname><given-names>T.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0037" contrib-type="author"><name><surname>Marks</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0038" contrib-type="author"><name><surname>Beau</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0039" contrib-type="author"><name><surname>Tableriou</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0040" contrib-type="author"><name><surname>Griffin</surname><given-names>B.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0041" contrib-type="author"><name><surname>Shani</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0042" contrib-type="author"><name><surname>Stokes‐McCarthy</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0043" contrib-type="author"><name><surname>Tan‐Augenstein</surname><given-names>G.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0044" contrib-type="author"><name><surname>Pace</surname><given-names>G.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0045" contrib-type="author"><name><surname>Brosnan</surname><given-names>H.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0046" contrib-type="author"><name><surname>Hayes</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0047" contrib-type="author"><name><surname>Mancl</surname><given-names>K.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0048" contrib-type="author"><name><surname>Maassen</surname><given-names>K.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0049" contrib-type="author"><name><surname>Fintel</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0050" contrib-type="author"><name><surname>Karpf</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0051" contrib-type="author"><name><surname>Abraham</surname><given-names>T.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0052" contrib-type="author"><name><surname>Campione</surname><given-names>K.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0053" contrib-type="author"><name><surname>Martin</surname><given-names>E.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0054" contrib-type="author"><name><surname>Bello</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0055" contrib-type="author"><name><surname>Viera Fleetwood</surname><given-names>I.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0056" contrib-type="author"><name><surname>Tinetti</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0057" contrib-type="author"><name><surname>Rock</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0058" contrib-type="author"><name><surname>Simonson</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0059" contrib-type="author"><name><surname>Barnes</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0060" contrib-type="author"><name><surname>Letexier</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0061" contrib-type="author"><name><surname>Strothman</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0062" contrib-type="author"><name><surname>Mattson</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0063" contrib-type="author"><name><surname>Albert Shoultz</surname><given-names>C.</given-names><suffix>III</suffix></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0064" contrib-type="author"><name><surname>Ali</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0065" contrib-type="author"><name><surname>Abbott</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0066" contrib-type="author"><name><surname>Medeiros</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0067" contrib-type="author"><name><surname>McKeon</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0068" contrib-type="author"><name><surname>Nichols</surname><given-names>A.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0069" contrib-type="author"><name><surname>Edwards</surname><given-names>T.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0070" contrib-type="author"><name><surname>Watts</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0071" contrib-type="author"><name><surname>Alley</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0072" contrib-type="author"><name><surname>Romanelli</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0073" contrib-type="author"><name><surname>Steffen</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0074" contrib-type="author"><name><surname>Henschel</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0075" contrib-type="author"><name><surname>Teller</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0076" contrib-type="author"><name><surname>Froehlich</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0077" contrib-type="author"><name><surname>Bess</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0078" contrib-type="author"><name><surname>Warnica</surname><given-names>W.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0079" contrib-type="author"><name><surname>Smith</surname><given-names>B.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0080" contrib-type="author"><name><surname>Eichman</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0081" contrib-type="author"><name><surname>Scarcelli</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0082" contrib-type="author"><name><surname>Badhwar</surname><given-names>N.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0083" contrib-type="author"><name><surname>Malone</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0084" contrib-type="author"><name><surname>Green</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0085" contrib-type="author"><name><surname>Iyer</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0086" contrib-type="author"><name><surname>Germany</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0087" contrib-type="author"><name><surname>Murray</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0088" contrib-type="author"><name><surname>Straughn</surname><given-names>G.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0089" contrib-type="author"><name><surname>Drennan</surname><given-names>K.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0090" contrib-type="author"><name><surname>Marroquin</surname><given-names>O.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0091" contrib-type="author"><name><surname>Dennis</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0092" contrib-type="author"><name><surname>Farrow</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0093" contrib-type="author"><name><surname>Baxendell</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0094" contrib-type="author"><name><surname>Grate</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0095" contrib-type="author"><name><surname>Enlow</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0096" contrib-type="author"><name><surname>Zareba</surname><given-names>W.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0097" contrib-type="author"><name><surname>Chaudhary</surname><given-names>I.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0098" contrib-type="author"><name><surname>Laduke</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0099" contrib-type="author"><name><surname>Conary‐Rocco</surname><given-names>V.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0100" contrib-type="author"><name><surname>Caufield</surname><given-names>L.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0101" contrib-type="author"><name><surname>Patterson</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0102" contrib-type="author"><name><surname>Warner</surname><given-names>A.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0103" contrib-type="author"><name><surname>Johnson</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0104" contrib-type="author"><name><surname>Germano</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0105" contrib-type="author"><name><surname>Drewes</surname><given-names>W.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0106" contrib-type="author"><name><surname>George</surname><given-names>B.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0107" contrib-type="author"><name><surname>Yoo</surname><given-names>B.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0108" contrib-type="author"><name><surname>Patel</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0109" contrib-type="author"><name><surname>Bonow</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0110" contrib-type="author"><name><surname>Cuffe</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0111" contrib-type="author"><name><surname>Dyer</surname><given-names>A.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0112" contrib-type="author"><name><surname>Greenland</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0113" contrib-type="author"><name><surname>Goldberger</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0114" contrib-type="author"><name><surname>O’Rourke</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0115" contrib-type="author"><name><surname>Rosenberg</surname><given-names>Y.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0116" contrib-type="author"><name><surname>Shah</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0117" contrib-type="author"><name><surname>Byington</surname><given-names>R.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0118" contrib-type="author"><name><surname>Feng</surname><given-names>Z.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0119" contrib-type="author"><name><surname>Goldstein</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0120" contrib-type="author"><name><surname>Kirkpatrick</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0121" contrib-type="author"><name><surname>Love</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0122" contrib-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0123" contrib-type="author"><name><surname>Rosenberg</surname><given-names>Y.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0124" contrib-type="author"><name><surname>Goldberg</surname><given-names>S.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0125" contrib-type="author"><name><surname>Kwak</surname><given-names>M.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0126" contrib-type="author"><name><surname>Rao</surname><given-names>A.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0127" contrib-type="author"><name><surname>Srinivas</surname><given-names>P.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0128" contrib-type="author"><name><surname>Goldberger</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0129" contrib-type="author"><name><surname>Ball</surname><given-names>C.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0130" contrib-type="author"><name><surname>Cahill</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0131" contrib-type="author"><name><surname>Schaechter</surname><given-names>A.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0132" contrib-type="author"><name><surname>Alexander</surname><given-names>D.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0133" contrib-type="author"><name><surname>Ma</surname><given-names>K.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0134" contrib-type="author"><name><surname>Plant</surname><given-names>T.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0135" contrib-type="author"><name><surname>Rosenfeld</surname><given-names>A.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0136" contrib-type="author"><name><surname>Scofic</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0137" contrib-type="author"><name><surname>Simon</surname><given-names>J.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib><contrib id="jah36206-cr-0138" contrib-type="author"><name><surname>Subačius</surname><given-names>H.</given-names></name><xref rid="jah36206-cr-0006" ref-type="contrib"/></contrib></contrib-group>
</collab>
                  <xref rid="jah36206-note-0001" ref-type="author-notes">
                    <sup>*</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah36206-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>University of Miami Miller School of Medicine</institution>
                <city>Miami</city>
                <named-content content-type="country-part">FL</named-content>
              </aff>
              <aff id="jah36206-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Division of Research and Optimal Patient Care</named-content>
                <institution>American College of Surgeons</institution>
                <city>Chicago</city>
                <named-content content-type="country-part">IL</named-content>
              </aff>
              <aff id="jah36206-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">UPMC Heart and Vascular Institute and Division of Cardiology</named-content>
                <institution>University of Pittsburgh</institution>
                <named-content content-type="country-part">PA</named-content>
              </aff>
              <aff id="jah36206-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Arkansas Heart Hospital</institution>
                <city>Little Rock</city>
                <named-content content-type="country-part">AR</named-content>
              </aff>
              <aff id="jah36206-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Park Nicollet Methodist Hospital</institution>
                <city>St. Louis Park</city>
                <named-content content-type="country-part">MN</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Jeffrey J. Goldberger, MD, MBA, Division of Cardiology, University of Miami Miller School of Medicine, 1124 NW 14th St., Miami, FL 33136. E‐mail: <email>j-goldberger@miami.edu</email>
<break/>
</corresp>
                <fn id="jah36206-note-0001">
                  <label>*</label>
                  <p>A complete list of the OBTAIN Investigators can be found in the Appendix at the end of the article.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>06</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>20</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <volume>10</volume>
              <issue seq="80">14</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v10.14</issue-id>
              <elocation-id>e019017</elocation-id>
              <history>
                <date date-type="received">
                  <day>19</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>02</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-10-e019017.pdf"/>
              <abstract id="jah36206-abs-0001">
                <sec id="jah36206-sec-0001">
                  <title>Background</title>
                  <p>Although beta‐blockers are recommended following myocardial infarction (MI), the benefits of long‐term treatment have not been established. The study's aim was to evaluate beta‐blocker efficacy by dose in 1‐year post‐MI survivors.</p>
                </sec>
                <sec id="jah36206-sec-0002">
                  <title>Methods and Results</title>
                  <p>The OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) registry included 7057 patients with acute MI, with 6077 one‐year survivors. For this landmark analysis, beta‐blocker dose status was available in 3004 patients and analyzed by use (binary) and dose at 1 year after MI. Doses were classified as no beta‐blocker and &gt;0% to 12.5%, &gt;12.5% to 25%, &gt;25% to 50%, and &gt;50% of target doses used in randomized clinical trials. Age was 63 to 64 years, and approximately two thirds were men. Median follow‐up duration was 1.05 years (interquartile range, 0.98–1.22). When analyzed dichotomously, beta‐blocker therapy was not associated with improved survival. When analyzed by dose, propensity score analysis showed significantly increased mortality in the no–beta‐blocker group (hazard ratio,1.997; 95% CI, 1.118–3.568; <italic toggle="yes">P</italic>&lt;0.02), the &gt;0% to 12.5% group (hazard ratio, 1.817; 95% CI, 1.094–3.016; <italic toggle="yes">P</italic>&lt;0.02), and the &gt;25% to 50% group (hazard ratio, 1.764; 95% CI, 1.105–2.815; <italic toggle="yes">P</italic>&lt;0.02), compared with the &gt;12.5% to 25% dose group. The mortality in the full‐dose group was not significantly higher (hazard ratio, 1.196; 95% CI, 0.687–2.083). In subgroup analyses, only history of congestive heart failure demonstrated significant interaction with beta‐blocker effects on survival.</p>
                </sec>
                <sec id="jah36206-sec-0003">
                  <title>Conclusions</title>
                  <p>This analysis suggests that patients treated with &gt;12.5% to 25% of the target dose used in prior randomized clinical trials beyond 1 year after MI may have enhanced survival compared with no beta‐blocker and other beta‐blocker doses. A new paradigm for post‐MI beta‐blocker therapy is needed that addresses which patients should be treated, for how long, and at what dose.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah36206-kwd-0001">beta‐blocker</kwd>
                <kwd id="jah36206-kwd-0002">landmark analysis</kwd>
                <kwd id="jah36206-kwd-0003">myocardial infarction</kwd>
                <kwd id="jah36206-kwd-0004">survival</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Myocardial Infarction</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>National Heart, Lung, and Blood Institute of the National Institutes of Health</funding-source>
                  <award-id>5U01HL080416</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>Miami Heart Research Institute</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="2"/>
                <page-count count="11"/>
                <word-count count="7947"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>July 20, 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.4 mode:remove_FC converted:02.08.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah36206-cit-1001">(<source>J Am Heart Assoc</source>. <year>2021</year>;<volume>10</volume>:<elocation-id>e019017</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.120.019017</pub-id>.)<pub-id pub-id-type="pmid">34227397</pub-id></mixed-citation>
              </p>
              <fn-group id="jah36206-ntgp-0001">
                <fn id="jah36206-note-0002">
                  <p>For Sources of Funding and Disclosures, see page 10.</p>
                </fn>
                <fn id="jah36206-note-0003">
                  <p>See Editorial by Schupp et al.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah36206-body-0001">
            <def-list list-content="abbreviations" id="jah36206-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>CAPRICORN</term>
                <def>
                  <p>Carvedilol Post‐Infarct Survival Control in LV Dysfunction</p>
                </def>
              </def-item>
              <def-item>
                <term>COMMIT</term>
                <def>
                  <p>Clopidogrel and Metoprolol in Myocardial Infarction Trial</p>
                </def>
              </def-item>
              <def-item>
                <term>CRUSADE</term>
                <def>
                  <p>Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines</p>
                </def>
              </def-item>
              <def-item>
                <term>OBTAIN</term>
                <def>
                  <p>Outcomes of Beta‐Blocker Therapy After Myocardial Infarction</p>
                </def>
              </def-item>
              <def-item>
                <term>VALIANT</term>
                <def>
                  <p>Valsartan in Acute Myocardial Infarction Trial</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah36206-blkfxd-0001">
                <sec id="jah36206-sec-0005">
                  <title>Clinical Perspective</title>
                  <sec id="jah36206-sec-0006">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah36206-list-0001">
                        <list-item>
                          <p>This 1‐year landmark analysis of the effects of beta‐blocker therapy on survival after myocardial infarction did not demonstrate overall improvement when analyzed dichotomously, on (all doses) versus off beta‐blocker therapy.</p>
                        </list-item>
                        <list-item>
                          <p>As noted in the original OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) report, there appeared to be a dose dependence of the benefit of beta‐blocker therapy on survival, even beyond 1 year after myocardial infarction, with benefit noted at one quarter the dose targeted in clinical trials demonstrating the benefit of beta‐blocker therapy.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah36206-sec-0007">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah36206-list-0002">
                        <list-item>
                          <p>Even in the modern era of management of myocardial infarction, with all of the newer therapies that have been implemented since the original beta‐blocker trials were performed, there is a signal for continued benefit of beta‐blocker therapy that requires further elucidation in prospective trials.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah36206-sec-0008">
              <p>The most recent guidelines<xref rid="jah36206-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah36206-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="jah36206-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="jah36206-bib-0004" ref-type="bibr"><sup>4</sup></xref> recommend beta‐blocker therapy after acute myocardial infarction (MI). These guidelines do not generally address duration of treatment, but treatment has been recommended for at least 3 years.<xref rid="jah36206-bib-0005" ref-type="bibr"><sup>5</sup></xref> The predominance of data supporting beta‐blocker use after MI derives from multiple randomized clinical trials performed in the 1970s and 1980s, before the standard use of some of the currently available therapies that also improve survival including primary percutaneous coronary intervention/thrombolysis, aspirin, statins, and angiotensin‐converting enzyme inhibitors. A meta‐analysis<xref rid="jah36206-bib-0006" ref-type="bibr"><sup>6</sup></xref> suggested that beta‐blockers are not effective in the postthrombolysis era, though this was driven largely by the findings of the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) trial.<xref rid="jah36206-bib-0007" ref-type="bibr"><sup>7</sup></xref> Although early trials, such as the Norwegian timolol trial,<xref rid="jah36206-bib-0008" ref-type="bibr"><sup>8</sup></xref> demonstrated preservation of the improved outcome associated with beta‐blocker use for as long as 6 years, the survival curves continue to diverge only slightly beyond 1 year and for a limited period of time, raising the question whether beta‐blocker use should be continued beyond this time period. None of the randomized clinical trials performed a landmark analysis of the efficacy of beta‐blocker therapy beyond 1 year after MI.</p>
              <p>The OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) study<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> was a multicenter observational registry designed to evaluate the effect of beta‐blocker dose on outcome after MI. Although the study hypothesized that greater benefit would be observed with the use of beta‐blocker doses that were targeted in the randomized clinical trials that demonstrated the efficacy of beta‐blocker therapy after MI compared with lower doses, no such benefit was observed, though there was an overall benefit to beta‐blocker therapy. The present analysis evaluates the efficacy of continued beta‐blocker therapy and the effect of dose among patients who survived 1 year after myocardial infarction. Based upon the primary OBTAIN analysis,<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> we postulated that the optimum survival would be noted in patients treated with 25% of the target doses of beta‐blockers used in the randomized clinical trials.</p>
            </sec>
            <sec sec-type="methods" id="jah36206-sec-0009">
              <title>Methods</title>
              <sec id="jah36206-sec-0010">
                <title>Patient Population</title>
                <p>The data that support the findings of this study are available from the corresponding author upon reasonable request. Detailed information about the OBTAIN study design has been published.<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> Briefly, the OBTAIN registry enrolled 7057 patients with acute MI from 26 participating centers (25 in the United States and 1 in Canada). Acute MI was diagnosed by (1) either creatine kinase elevation &gt;2 times or troponin elevation &gt;3 times the upper limit of normal and (2) either chest pain (or equivalent symptoms suggestive of MI) or electrocardiographic changes consistent with MI. The study was initiated in 2007 and enrolled patients through 2011. All data were collected at the site, and deidentified patient information was entered in a web‐based electronic data capture system. Vital status was assessed by chart review, the Social Security Administration Death Master File, or direct communication with the patient/family. Follow‐up beta‐blocker dosing was recorded when available. Particularly for sites that participated in the original version of the registry, longer term follow‐up (3+ years) was available. The study was funded by the National Heart, Lung and Blood Institute. The study was approved by each site's institutional review board with a waiver of consent for registry enrollment. Participating centers and study committees and personnel are listed in the original report.<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref>
</p>
                <p>The present analysis focuses on the 6077 patients who survived 1 year after their acute MI. One‐year beta‐blocker dose information was available in 3004 patients. Table <xref rid="jah36206-tbl-0001" ref-type="table">1</xref> shows the characteristics of these patients compared with the 3073 patients in whom beta‐blocker dosing information was not available.</p>
                <table-wrap position="float" id="jah36206-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Characteristics of the Study Population and Mortality According to Beta‐Blocker Dose at 1 Year</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="3" valign="top" colspan="1"/>
                        <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">1‐y Follow‐Up Information</th>
                        <th align="center" rowspan="3" valign="top" colspan="1"><italic toggle="yes">P</italic> Value No vs Yes</th>
                        <th align="center" rowspan="2" valign="top" colspan="1">Not on Beta‐Blocker</th>
                        <th align="center" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Beta‐Blocker Dose, % of Target Dose</th>
                        <th align="center" rowspan="3" valign="top" colspan="1"><italic toggle="yes">P</italic> Value Among 5 Doses</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">No</th>
                        <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Yes</th>
                        <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">&gt;0%–12.5%</th>
                        <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">&gt;12.5%–25%</th>
                        <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">&gt;25%–50%</th>
                        <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">&gt;50%</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">n=3073</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n=3004</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n=319</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n=597</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n=906</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n=728</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">n=454</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Patient characteristics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td>
                        <td align="left" rowspan="1" colspan="1">62.8±13.6</td>
                        <td align="left" rowspan="1" colspan="1">63.0±13.1</td>
                        <td align="left" rowspan="1" colspan="1">0.46</td>
                        <td align="left" rowspan="1" colspan="1">62.9±14</td>
                        <td align="left" rowspan="1" colspan="1">64.3±13.3</td>
                        <td align="left" rowspan="1" colspan="1">62.4±13.1</td>
                        <td align="left" rowspan="1" colspan="1">63±12.8</td>
                        <td align="left" rowspan="1" colspan="1">62.7±12.5</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.09</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Men</td>
                        <td align="left" rowspan="1" colspan="1">2099 (68.3)</td>
                        <td align="left" rowspan="1" colspan="1">2053 (68.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.98</td>
                        <td align="left" rowspan="1" colspan="1">195 (61.1)</td>
                        <td align="left" rowspan="1" colspan="1">389 (65.2)</td>
                        <td align="left" rowspan="1" colspan="1">624 (68.9)</td>
                        <td align="left" rowspan="1" colspan="1">514 (70.6)</td>
                        <td align="left" rowspan="1" colspan="1">331 (72.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.002</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="10" rowspan="1">Race</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">White</td>
                        <td align="left" rowspan="1" colspan="1">2312 (75.2)</td>
                        <td align="left" rowspan="1" colspan="1">2525 (84.1)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">265 (83.1)</td>
                        <td align="left" rowspan="1" colspan="1">521 (87.3)</td>
                        <td align="left" rowspan="1" colspan="1">758 (83.7)</td>
                        <td align="left" rowspan="1" colspan="1">612 (84.1)</td>
                        <td align="left" rowspan="1" colspan="1">369 (81.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Black</td>
                        <td align="left" rowspan="1" colspan="1">375 (12.2)</td>
                        <td align="left" rowspan="1" colspan="1">254 (8.5)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">30 (9.4)</td>
                        <td align="left" rowspan="1" colspan="1">38 (6.4)</td>
                        <td align="left" rowspan="1" colspan="1">78 (8.6)</td>
                        <td align="left" rowspan="1" colspan="1">61 (8.4)</td>
                        <td align="left" rowspan="1" colspan="1">47 (10.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.21</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asian</td>
                        <td align="left" rowspan="1" colspan="1">65 (2.1)</td>
                        <td align="left" rowspan="1" colspan="1">80 (2.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.16</td>
                        <td align="left" rowspan="1" colspan="1">5 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">12 (2)</td>
                        <td align="left" rowspan="1" colspan="1">22 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">24 (3.3)</td>
                        <td align="left" rowspan="1" colspan="1">17 (3.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.21</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">American Indian</td>
                        <td align="left" rowspan="1" colspan="1">12 (0.4)</td>
                        <td align="left" rowspan="1" colspan="1">17 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.32</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">8 (0.9)</td>
                        <td align="left" rowspan="1" colspan="1">4 (0.5)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.53</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Pacific Islander</td>
                        <td align="left" rowspan="1" colspan="1">11 (0.4)</td>
                        <td align="left" rowspan="1" colspan="1">4 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.12</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.27</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Unknown</td>
                        <td align="left" rowspan="1" colspan="1">303 (9.9)</td>
                        <td align="left" rowspan="1" colspan="1">127 (4.2)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">17 (5.3)</td>
                        <td align="left" rowspan="1" colspan="1">24 (4)</td>
                        <td align="left" rowspan="1" colspan="1">40 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1">25 (3.4)</td>
                        <td align="left" rowspan="1" colspan="1">21 (4.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.66</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Other</td>
                        <td align="left" rowspan="1" colspan="1">5 (0.2)</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.73</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.3)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.20</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic</td>
                        <td align="left" rowspan="1" colspan="1">295 (10.4)</td>
                        <td align="left" rowspan="1" colspan="1">150 (5.3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">21 (7.2)</td>
                        <td align="left" rowspan="1" colspan="1">30 (5.4)</td>
                        <td align="left" rowspan="1" colspan="1">45 (5.3)</td>
                        <td align="left" rowspan="1" colspan="1">30 (4.3)</td>
                        <td align="left" rowspan="1" colspan="1">24 (5.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                        <td align="left" rowspan="1" colspan="1">29.1±6.4</td>
                        <td align="left" rowspan="1" colspan="1">29.4±6.5</td>
                        <td align="left" rowspan="1" colspan="1">0.16</td>
                        <td align="left" rowspan="1" colspan="1">28.8±6.1</td>
                        <td align="left" rowspan="1" colspan="1">28.2±6.3</td>
                        <td align="left" rowspan="1" colspan="1">29.3±6.2</td>
                        <td align="left" rowspan="1" colspan="1">29.8±6.8</td>
                        <td align="left" rowspan="1" colspan="1">30.8±6.9</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Medical history</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td>
                        <td align="left" rowspan="1" colspan="1">982 (32)</td>
                        <td align="left" rowspan="1" colspan="1">889 (29.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.04</td>
                        <td align="left" rowspan="1" colspan="1">81 (25.4)</td>
                        <td align="left" rowspan="1" colspan="1">143 (24)</td>
                        <td align="left" rowspan="1" colspan="1">249 (27.5)</td>
                        <td align="left" rowspan="1" colspan="1">227 (31.2)</td>
                        <td align="left" rowspan="1" colspan="1">189 (41.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">2047 (66.7)</td>
                        <td align="left" rowspan="1" colspan="1">2003 (66.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.97</td>
                        <td align="left" rowspan="1" colspan="1">187 (58.6)</td>
                        <td align="left" rowspan="1" colspan="1">339 (56.8)</td>
                        <td align="left" rowspan="1" colspan="1">602 (66.4)</td>
                        <td align="left" rowspan="1" colspan="1">510 (70.1)</td>
                        <td align="left" rowspan="1" colspan="1">365 (80.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td>
                        <td align="left" rowspan="1" colspan="1">1572 (51.3)</td>
                        <td align="left" rowspan="1" colspan="1">1714 (57.1)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">168 (52.7)</td>
                        <td align="left" rowspan="1" colspan="1">322 (53.9)</td>
                        <td align="left" rowspan="1" colspan="1">482 (53.3)</td>
                        <td align="left" rowspan="1" colspan="1">432 (59.3)</td>
                        <td align="left" rowspan="1" colspan="1">310 (68.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous MI</td>
                        <td align="left" rowspan="1" colspan="1">602 (19.6)</td>
                        <td align="left" rowspan="1" colspan="1">286 (9.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.95</td>
                        <td align="left" rowspan="1" colspan="1">55 (17.2)</td>
                        <td align="left" rowspan="1" colspan="1">86 (14.4)</td>
                        <td align="left" rowspan="1" colspan="1">180 (19.9)</td>
                        <td align="left" rowspan="1" colspan="1">160 (22)</td>
                        <td align="left" rowspan="1" colspan="1">129 (28.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">CABG history</td>
                        <td align="left" rowspan="1" colspan="1">394 (12.8)</td>
                        <td align="left" rowspan="1" colspan="1">610 (20.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                        <td align="left" rowspan="1" colspan="1">21 (6.6)</td>
                        <td align="left" rowspan="1" colspan="1">54 (9)</td>
                        <td align="left" rowspan="1" colspan="1">99 (10.9)</td>
                        <td align="left" rowspan="1" colspan="1">102 (14)</td>
                        <td align="left" rowspan="1" colspan="1">79 (17.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">CHF history</td>
                        <td align="left" rowspan="1" colspan="1">287<xref rid="jah36206-note-0005" ref-type="table-fn">*</xref> (9.4)</td>
                        <td align="left" rowspan="1" colspan="1">355 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                        <td align="left" rowspan="1" colspan="1">27 (8.5)</td>
                        <td align="left" rowspan="1" colspan="1">38 (6.4)</td>
                        <td align="left" rowspan="1" colspan="1">56 (6.2)</td>
                        <td align="left" rowspan="1" colspan="1">66 (9.1)</td>
                        <td align="left" rowspan="1" colspan="1">52 (11.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.005</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ESRD</td>
                        <td align="left" rowspan="1" colspan="1">78 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">297 (9.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.07</td>
                        <td align="left" rowspan="1" colspan="1">9 (2.8)</td>
                        <td align="left" rowspan="1" colspan="1">9 (1.5)</td>
                        <td align="left" rowspan="1" colspan="1">22 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">24 (3.3)</td>
                        <td align="left" rowspan="1" colspan="1">20 (4.4)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.06</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">CVA/TIA</td>
                        <td align="left" rowspan="1" colspan="1">291 (9.5)</td>
                        <td align="left" rowspan="1" colspan="1">106 (3.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.77</td>
                        <td align="left" rowspan="1" colspan="1">31 (9.7)</td>
                        <td align="left" rowspan="1" colspan="1">53 (8.9)</td>
                        <td align="left" rowspan="1" colspan="1">68 (7.5)</td>
                        <td align="left" rowspan="1" colspan="1">71 (9.8)</td>
                        <td align="left" rowspan="1" colspan="1">63 (13.9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.006</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">COPD</td>
                        <td align="left" rowspan="1" colspan="1">313 (10.2)</td>
                        <td align="left" rowspan="1" colspan="1">239 (8)</td>
                        <td align="left" rowspan="1" colspan="1">0.05</td>
                        <td align="left" rowspan="1" colspan="1">41 (12.9)</td>
                        <td align="left" rowspan="1" colspan="1">48 (8.0)</td>
                        <td align="left" rowspan="1" colspan="1">83 (9.2)</td>
                        <td align="left" rowspan="1" colspan="1">57 (7.8)</td>
                        <td align="left" rowspan="1" colspan="1">37 (8.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.09</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">MI characteristics</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="10" rowspan="1">STEMI</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Anterior</td>
                        <td align="left" rowspan="1" colspan="1">418 (31.5)</td>
                        <td align="left" rowspan="1" colspan="1">484 (34.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.08</td>
                        <td align="left" rowspan="1" colspan="1">43 (31.4)</td>
                        <td align="left" rowspan="1" colspan="1">111 (34.6)</td>
                        <td align="left" rowspan="1" colspan="1">129 (30.6)</td>
                        <td align="left" rowspan="1" colspan="1">127 (37.5)</td>
                        <td align="left" rowspan="1" colspan="1">74 (41.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.08</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Inferior/posterior</td>
                        <td align="left" rowspan="1" colspan="1">690 (51.9)</td>
                        <td align="left" rowspan="1" colspan="1">704 (50.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.43</td>
                        <td align="left" rowspan="1" colspan="1">76 (55.5)</td>
                        <td align="left" rowspan="1" colspan="1">172 (53.6)</td>
                        <td align="left" rowspan="1" colspan="1">215 (51.1)</td>
                        <td align="left" rowspan="1" colspan="1">169 (49.9)</td>
                        <td align="left" rowspan="1" colspan="1">72 (40.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Thrombolytic therapy</td>
                        <td align="left" rowspan="1" colspan="1">201 (15.1)</td>
                        <td align="left" rowspan="1" colspan="1">172 (12.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.03</td>
                        <td align="left" rowspan="1" colspan="1">14 (10.2)</td>
                        <td align="left" rowspan="1" colspan="1">25 (7.8)</td>
                        <td align="left" rowspan="1" colspan="1">58 (13.8)</td>
                        <td align="left" rowspan="1" colspan="1">50 (14.7)</td>
                        <td align="left" rowspan="1" colspan="1">25 (14)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.04</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary PCI</td>
                        <td align="left" rowspan="1" colspan="1">1131 (85.1)</td>
                        <td align="left" rowspan="1" colspan="1">11 143 (81.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.02</td>
                        <td align="left" rowspan="1" colspan="1">111 (81)</td>
                        <td align="left" rowspan="1" colspan="1">277 (86.3)</td>
                        <td align="left" rowspan="1" colspan="1">357 (84.8)</td>
                        <td align="left" rowspan="1" colspan="1">277 (81.7)</td>
                        <td align="left" rowspan="1" colspan="1">121 (67.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">In‐hospital revascularization, nonprimary PCI and CABG</td>
                        <td align="left" rowspan="1" colspan="1">193 (14.5)</td>
                        <td align="left" rowspan="1" colspan="1">261 (18.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.004</td>
                        <td align="left" rowspan="1" colspan="1">32 (23.4)</td>
                        <td align="left" rowspan="1" colspan="1">53 (16.5)</td>
                        <td align="left" rowspan="1" colspan="1">71 (16.9)</td>
                        <td align="left" rowspan="1" colspan="1">58 (17.1)</td>
                        <td align="left" rowspan="1" colspan="1">47 (26.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Diagnostic angiography</td>
                        <td align="left" rowspan="1" colspan="1">68 (5.1)</td>
                        <td align="left" rowspan="1" colspan="1">62 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.41</td>
                        <td align="left" rowspan="1" colspan="1">6 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1">8 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">15 (3.6)</td>
                        <td align="left" rowspan="1" colspan="1">16 (4.7)</td>
                        <td align="left" rowspan="1" colspan="1">17 (9.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.006</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="10" rowspan="1">NSTEMI</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Thrombolytic therapy</td>
                        <td align="left" rowspan="1" colspan="1">73 (4.2)</td>
                        <td align="left" rowspan="1" colspan="1">26 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">3 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.7)</td>
                        <td align="left" rowspan="1" colspan="1">12 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">5 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">4 (1.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.41</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Primary PCI</td>
                        <td align="left" rowspan="1" colspan="1">769 (44.1)</td>
                        <td align="left" rowspan="1" colspan="1">673 (41.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.20</td>
                        <td align="left" rowspan="1" colspan="1">73 (40.1)</td>
                        <td align="left" rowspan="1" colspan="1">141 (51.1)</td>
                        <td align="left" rowspan="1" colspan="1">227 (46.8)</td>
                        <td align="left" rowspan="1" colspan="1">140 (36)</td>
                        <td align="left" rowspan="1" colspan="1">92 (33.5)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">In‐hospital revascularization, nonprimary PCI and CABG</td>
                        <td align="left" rowspan="1" colspan="1">573 (32.9)</td>
                        <td align="left" rowspan="1" colspan="1">534 (33.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.82</td>
                        <td align="left" rowspan="1" colspan="1">56 (30.8)</td>
                        <td align="left" rowspan="1" colspan="1">81 (29.3)</td>
                        <td align="left" rowspan="1" colspan="1">165 (34)</td>
                        <td align="left" rowspan="1" colspan="1">138 (35.5)</td>
                        <td align="left" rowspan="1" colspan="1">94 (34.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.48</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Diagnostic angiography</td>
                        <td align="left" rowspan="1" colspan="1">286 (16.4)</td>
                        <td align="left" rowspan="1" colspan="1">233 (14.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.13</td>
                        <td align="left" rowspan="1" colspan="1">33 (18.1)</td>
                        <td align="left" rowspan="1" colspan="1">36 (13)</td>
                        <td align="left" rowspan="1" colspan="1">58 (12)</td>
                        <td align="left" rowspan="1" colspan="1">63 (16.2)</td>
                        <td align="left" rowspan="1" colspan="1">43 (15.6)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.19</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ICD</td>
                        <td align="left" rowspan="1" colspan="1">105 (3.4)</td>
                        <td align="left" rowspan="1" colspan="1">86 (2.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.22</td>
                        <td align="left" rowspan="1" colspan="1">8 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">9 (1.5)</td>
                        <td align="left" rowspan="1" colspan="1">20 (2.2)</td>
                        <td align="left" rowspan="1" colspan="1">25 (3.4)</td>
                        <td align="left" rowspan="1" colspan="1">24 (5.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.003</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Admission SBP, mm Hg</td>
                        <td align="left" rowspan="1" colspan="1">141.2±29.9</td>
                        <td align="left" rowspan="1" colspan="1">140.7±29.8</td>
                        <td align="left" rowspan="1" colspan="1">0.48</td>
                        <td align="left" rowspan="1" colspan="1">138.6±31.6</td>
                        <td align="left" rowspan="1" colspan="1">136.6±27.8</td>
                        <td align="left" rowspan="1" colspan="1">141±28.5</td>
                        <td align="left" rowspan="1" colspan="1">142.3±30.7</td>
                        <td align="left" rowspan="1" colspan="1">144.4±31.7</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.0002</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Admission HR, beats/min</td>
                        <td align="left" rowspan="1" colspan="1">82.2±20.6</td>
                        <td align="left" rowspan="1" colspan="1">82.1±21.9</td>
                        <td align="left" rowspan="1" colspan="1">0.81</td>
                        <td align="left" rowspan="1" colspan="1">80.0±22.2</td>
                        <td align="left" rowspan="1" colspan="1">79.9±19.9</td>
                        <td align="left" rowspan="1" colspan="1">81.3±21.3</td>
                        <td align="left" rowspan="1" colspan="1">82.3±21.8</td>
                        <td align="left" rowspan="1" colspan="1">87.6±24.2</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart failure on admission</td>
                        <td align="left" rowspan="1" colspan="1">262 (8.5)</td>
                        <td align="left" rowspan="1" colspan="1">266 (8.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.07</td>
                        <td align="left" rowspan="1" colspan="1">32 (10)</td>
                        <td align="left" rowspan="1" colspan="1">55 (9.2)</td>
                        <td align="left" rowspan="1" colspan="1">83 (9.2)</td>
                        <td align="left" rowspan="1" colspan="1">76 (10.4)</td>
                        <td align="left" rowspan="1" colspan="1">51 (11.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.73</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LVEF</td>
                        <td align="left" rowspan="1" colspan="1">47.1±13.1</td>
                        <td align="left" rowspan="1" colspan="1">47.9±12.3</td>
                        <td align="left" rowspan="1" colspan="1">0.02</td>
                        <td align="left" rowspan="1" colspan="1">49.8±12.4</td>
                        <td align="left" rowspan="1" colspan="1">47.6±12.4</td>
                        <td align="left" rowspan="1" colspan="1">47.9±12.2</td>
                        <td align="left" rowspan="1" colspan="1">47.8±11.8</td>
                        <td align="left" rowspan="1" colspan="1">46.7±12.7</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Troponin, ng/mL</td>
                        <td align="left" rowspan="1" colspan="1">8.1 (2–31.6)</td>
                        <td align="left" rowspan="1" colspan="1">6.2 (1.8–24.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.004</td>
                        <td align="left" rowspan="1" colspan="1">6.3 (1.9–29.4)</td>
                        <td align="left" rowspan="1" colspan="1">11.7 (3–41.9)</td>
                        <td align="left" rowspan="1" colspan="1">6.6 (1.9–25.4)</td>
                        <td align="left" rowspan="1" colspan="1">5 (1.4–17.3)</td>
                        <td align="left" rowspan="1" colspan="1">3.8 (1.1–16.2)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">LOS median</td>
                        <td align="left" rowspan="1" colspan="1">5 (4–8)</td>
                        <td align="left" rowspan="1" colspan="1">5 (3–7)</td>
                        <td align="left" rowspan="1" colspan="1">0.20</td>
                        <td align="left" rowspan="1" colspan="1">4 (3–7)</td>
                        <td align="left" rowspan="1" colspan="1">4 (3–7)</td>
                        <td align="left" rowspan="1" colspan="1">4 (3–7)</td>
                        <td align="left" rowspan="1" colspan="1">5 (4–8)</td>
                        <td align="left" rowspan="1" colspan="1">5 (4–9)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Beta‐blocker dose, % target</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mode, % taking mode dose</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">12.5 (90.5)</td>
                        <td align="left" rowspan="1" colspan="1">25.0 (98.3)</td>
                        <td align="left" rowspan="1" colspan="1">50 (94.2)</td>
                        <td align="left" rowspan="1" colspan="1">100 (70.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Metoprolol</td>
                        <td align="left" rowspan="1" colspan="1">1841 (59.9)</td>
                        <td align="left" rowspan="1" colspan="1">1979 (65.9)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">155 (48.6)</td>
                        <td align="left" rowspan="1" colspan="1">415 (69.5)</td>
                        <td align="left" rowspan="1" colspan="1">657 (72.5)</td>
                        <td align="left" rowspan="1" colspan="1">475 (65.2)</td>
                        <td align="left" rowspan="1" colspan="1">277 (61)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Carvedilol</td>
                        <td align="left" rowspan="1" colspan="1">757 (24.6)</td>
                        <td align="left" rowspan="1" colspan="1">584 (19.4)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                        <td align="left" rowspan="1" colspan="1">40 (12.5)</td>
                        <td align="left" rowspan="1" colspan="1">136 (22.8)</td>
                        <td align="left" rowspan="1" colspan="1">161 (17.8)</td>
                        <td align="left" rowspan="1" colspan="1">138 (19)</td>
                        <td align="left" rowspan="1" colspan="1">109 (24)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.0002</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Discharge medications</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ASA</td>
                        <td align="left" rowspan="1" colspan="1">2853 (92.8)</td>
                        <td align="left" rowspan="1" colspan="1">2819 (93.8)</td>
                        <td align="left" rowspan="1" colspan="1">0.12</td>
                        <td align="left" rowspan="1" colspan="1">297 (93.1)</td>
                        <td align="left" rowspan="1" colspan="1">555 (93)</td>
                        <td align="left" rowspan="1" colspan="1">857 (94.6)</td>
                        <td align="left" rowspan="1" colspan="1">688 (94.5)</td>
                        <td align="left" rowspan="1" colspan="1">422 (93)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.53</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE‐I/ARB</td>
                        <td align="left" rowspan="1" colspan="1">2007 (65.3)</td>
                        <td align="left" rowspan="1" colspan="1">2097 (69.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1">192 (60.2)</td>
                        <td align="left" rowspan="1" colspan="1">390 (65.3)</td>
                        <td align="left" rowspan="1" colspan="1">634 (70)</td>
                        <td align="left" rowspan="1" colspan="1">537 (73.8)</td>
                        <td align="left" rowspan="1" colspan="1">344 (75.8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td>
                        <td align="left" rowspan="1" colspan="1">2554 (83.2)</td>
                        <td align="left" rowspan="1" colspan="1">2773 (92.3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1">276 (86.5)</td>
                        <td align="left" rowspan="1" colspan="1">554 (92.8)</td>
                        <td align="left" rowspan="1" colspan="1">846 (93.4)</td>
                        <td align="left" rowspan="1" colspan="1">677 (93)</td>
                        <td align="left" rowspan="1" colspan="1">420 (92.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.002</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Clopidogrel</td>
                        <td align="left" rowspan="1" colspan="1">2169 (70.6)</td>
                        <td align="left" rowspan="1" colspan="1">2157 (71.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1">209 (65.5)</td>
                        <td align="left" rowspan="1" colspan="1">466 (78.1)</td>
                        <td align="left" rowspan="1" colspan="1">694 (76.6)</td>
                        <td align="left" rowspan="1" colspan="1">565 (77.6)</td>
                        <td align="left" rowspan="1" colspan="1">317 (69.8)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dual antiplatelet</td>
                        <td align="left" rowspan="1" colspan="1">2077 (67.6)</td>
                        <td align="left" rowspan="1" colspan="1">2251 (74.9)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                        <td align="left" rowspan="1" colspan="1">201 (63.0)</td>
                        <td align="left" rowspan="1" colspan="1">439 (73.5)</td>
                        <td align="left" rowspan="1" colspan="1">670 (73.9)</td>
                        <td align="left" rowspan="1" colspan="1">546 (75.0)</td>
                        <td align="left" rowspan="1" colspan="1">301 (66.3)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="10" rowspan="1">Mortality, indexed to time of MI</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">2 y, Kaplan‐Meier %</td>
                        <td align="left" rowspan="1" colspan="1">140 (4.6)</td>
                        <td align="left" rowspan="1" colspan="1">121 (4.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.31</td>
                        <td align="left" rowspan="1" colspan="1">15 (4.7)</td>
                        <td align="left" rowspan="1" colspan="1">25 (4.2)</td>
                        <td align="left" rowspan="1" colspan="1">23 (2.5)</td>
                        <td align="left" rowspan="1" colspan="1">35 (4.8)</td>
                        <td align="left" rowspan="1" colspan="1">23 (5.1)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.09</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">3 y, Kaplan‐Meier %</td>
                        <td align="left" rowspan="1" colspan="1">206 (6.7)</td>
                        <td align="left" rowspan="1" colspan="1">152 (5.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.007</td>
                        <td align="left" rowspan="1" colspan="1">19 (6.0)</td>
                        <td align="left" rowspan="1" colspan="1">31 (5.2)</td>
                        <td align="left" rowspan="1" colspan="1">30 (3.3)</td>
                        <td align="left" rowspan="1" colspan="1">46 (6.3)</td>
                        <td align="left" rowspan="1" colspan="1">26 (5.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.06</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah36206-ntgp-0002">
                    <fn id="jah36206-note-0004">
                      <p>Values are mean±SD, n (%), or median (interquartile range). ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, aspirin; BMI, body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ESRD, end‐stage renal disease; HR, heart rate; ICD, implantable cardioverter‐defibrillator; LOS, length of stay; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non–ST‐segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST‐segment–elevation myocardial infarction; and TIA, transient ischemic attack.</p>
                    </fn>
                    <fn id="jah36206-note-0005">
                      <label>*</label>
                      <p>Includes patients with preadmission ICD and those discharged with an ICD.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Beta‐blocker therapy was not dictated by this study, but was managed individually by the patient's physician. As performed in the original report, beta‐blocker doses were indexed to the target doses (dose administered/target dose) used in prior clinical trials: metoprolol 200 mg/d,<xref rid="jah36206-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah36206-bib-0011" ref-type="bibr"><sup>11</sup></xref> carvedilol 50 mg/d<xref rid="jah36206-bib-0012" ref-type="bibr"><sup>12</sup></xref> (Coreg CR equivalent dose 80 mg/d), propranolol 180 mg/d,<xref rid="jah36206-bib-0013" ref-type="bibr"><sup>13</sup></xref> bisoprolol 10 mg/d,<xref rid="jah36206-bib-0014" ref-type="bibr"><sup>14</sup></xref> and atenolol 100 mg/d.<xref rid="jah36206-bib-0015" ref-type="bibr"><sup>15</sup></xref> Beta‐blocker doses were divided into 5 prespecified groups: no beta‐blocker, &gt;0% to 12.5%, &gt;12.5% to 25%, &gt;25% to 50%, and &gt;50% of the target dose.</p>
              </sec>
              <sec id="jah36206-sec-0011">
                <title>Statistical Analysis</title>
                <p>Patient characteristics were summarized as mean±SD or count (percent). Differences among groups were compared using χ<sup>2</sup> tests for categorical variables and analysis of variance for continuous variables. A distribution‐free rank sum test was used for variables that deviated from normality. Median (interquartile range) was used to summarize these variables. The Kaplan‐Meier method was used to calculate 2‐ and 3‐year post‐MI survival in each study group.</p>
                <p>Cox proportional hazards regression was used to test for the independent effects of beta‐blocker dosing on survival. Multivariable analysis included the covariates listed in Table <xref rid="jah36206-tbl-0001" ref-type="table">1</xref>. Random effects (shared frailty model) were also included for each of the recruiting hospitals to better model differences in mortality among them. Quadratic and cubic polynomial terms for continuous predictors were included to account for potential nonlinearity.</p>
                <p>Propensity score analysis was also performed as an alternative adjustment for patient differences in the 5 beta‐blocker dose groups, as previously reported.<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> To calculate the propensity score, we used mixed‐effects linear regression with random effects of the recruiting centers, continuous beta‐blocker dose (% of target dose) as a dependent variable, and the expanded control variable set reported in Table <xref rid="jah36206-tbl-0001" ref-type="table">1</xref>, including quadratic and cubic polynomial terms for continuous predictors. In that way, the propensity scores represent the predicted beta‐blocker dose given the extended set of patient characteristics. The propensity score was used as a control variable in the proportional hazards frailty regression model.</p>
                <p>Subgroup analysis was performed to test the hypothesis that the effect of 1‐year beta‐blocker status on subsequent mortality was equivalent in patients with (1) a history of congestive heart failure, (2) left ventricular ejection fraction ≤40%, (3) ST‐elevation MI, and (4) in‐hospital revascularization. Two versions of beta‐blocker status were used. First, we analyzed this variable in binary format, that is, patients who were on a beta‐blocker at 1 year versus those who were not. Subsequently, we used 5‐group analysis with all beta‐blocker dose categories including patients not on a beta‐blocker.</p>
                <p>All tests were 2‐tailed, and conventional 5% significance level was used. Analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah36206-sec-0012">
              <title>Results</title>
              <p>Table <xref rid="jah36206-tbl-0001" ref-type="table">1</xref> displays patient characteristics for the various treatment groups. Mean age was consistently 63 to 64 years across groups, and approximately two thirds were men, with a higher ratio in the higher‐dose groups. Other intergroup differences are shown in Table <xref rid="jah36206-tbl-0001" ref-type="table">1</xref>.</p>
              <p>In the 3073 patients for which no follow‐up beta‐blocker information was obtained, there were no significant differences in age and sex compared with those in whom 1‐year follow‐up beta‐blocker information was obtained, whereas several significant differences were observed in other baseline characteristics, MI characteristics, and notably in the discharge medications (Table <xref rid="jah36206-tbl-0001" ref-type="table">1</xref>). The 2‐year mortality in this 1‐year landmark analysis did not differ (4.6% versus 4.0% in those in whom follow‐up beta‐blocker information was available), whereas there was a higher 3‐year mortality (6.7% versus 5.1%, <italic toggle="yes">P</italic>=0.007).</p>
              <p>Among the 3004 one‐year post‐MI survivors in whom beta‐blocker dosing at 1 year was available, 319 (10.6%) were not treated with beta‐blockers, 597 (19.9%) were treated with &gt;0% to 12.5% of the target dose, 906 (30.2%) were treated with &gt;12.5% to 25% of the target dose, 728 (24.2%) were treated with &gt;25% to 50% of the target dose, and 454 (15.1%) were treated with &gt;50% of the target dose. Approximately 60% of the patients remained on the same dose at 1 year as at discharge. Figure <xref rid="jah36206-fig-0001" ref-type="fig">1</xref> shows the distribution of changing dose categories from the discharge dose.</p>
              <fig position="float" fig-type="Figure" id="jah36206-fig-0001">
                <label>Figure 1</label>
                <caption>
                  <title>Histogram of change in beta‐blocker (BB) dosing from discharge to 1 year.</title>
                  <p> </p>
                </caption>
                <graphic xlink:href="JAH3-10-e019017-g003" position="anchor" id="jats-graphic-1"/>
              </fig>
              <p>Of the 2685 patients treated with beta‐blockers, 1748 (65.1%) were treated with metoprolol, 653 (24.3%) were treated with carvedilol, 148 (5.5%) were treated with bisoprolol, 133 (5.0%) were treated with atenolol, and 3 (0.1%) were treated with propranolol.</p>
              <p>The median follow‐up duration after 1 year in this cohort of 1‐year post‐MI survivors was 1.05 years (interquartile range, 0.98–1.22). Overall, when analyzed as a dichotomous variable, beta‐blocker therapy was not associated with improved survival (unadjusted hazard ratio [HR], 0.892; 95% CI, 0.551–1.447; <italic toggle="yes">P</italic>=0.53; adjusted HR, 0.806; 95% CI, 0.485–1.340; <italic toggle="yes">P</italic>=0.40) compared with no beta‐blocker therapy. Figure <xref rid="jah36206-fig-0002" ref-type="fig">2</xref> shows the Kaplan‐Meier curves for the 5 beta‐blocker dose groups. The overall unadjusted effect of 1‐year beta‐blocker dose on subsequent survival was significant (<italic toggle="yes">P</italic>=0.03 by Cox proportional hazard analysis). As in the report of overall post‐MI survival in the OBTAIN study, the lowest observed mortality was in the &gt;12.5% to 25% dose group. Multivariable analysis identified that many of the tested parameters were independently related to survival (Table <xref rid="jah36206-tbl-0002" ref-type="table">2</xref>). The multivariable adjusted HRs relative to the &gt;12.5% to 25% target dose are shown in Figure <xref rid="jah36206-fig-0003" ref-type="fig">3</xref>. After multivariable adjustment, only the &gt;25% to 50% dose showed a statistically significant increased mortality (HR, 1.755; 95% CI, 1.095–2.813; <italic toggle="yes">P</italic>&lt;0.02) compared with the &gt;12.5% to 25% dose group, with borderline increases in most of the other doses. Propensity score analysis showed significantly increased mortality in the no beta‐blocker group (HR, 1.997; 95% CI, 1.118–3.568; <italic toggle="yes">P</italic>&lt;0.02), the &gt;0% to 12.5% group (HR, 1.817; 95% CI, 1.094–3.016; <italic toggle="yes">P</italic>&lt;0.02), and the &gt;25% to 50% group (HR, 1.764; 95% CI, 1.105–2.815; <italic toggle="yes">P</italic>&lt;0.02), compared with the &gt;12.5% to 25% dose group. The mortality in the full‐dose group was not significantly higher (HR, 1.196; 95% CI, 0.687–2.083). There were no significant differences in survival among any of the other dose groups, not including the &gt;12.5% to 25% dose group.</p>
              <fig position="float" fig-type="Figure" id="jah36206-fig-0002">
                <label>Figure 2</label>
                <caption>
                  <title>Kaplan‐Meier survival curves with landmark analysis from 1 year after myocardial infarction (MI) based on beta‐blocker (BB) dose at 1 year.</title>
                  <p>The top (&gt;12.5%–25%) and bottom (&gt;25–50%) survival curves are labeled. The legend provides the doses for the overlapping blue, red, and purple curves.</p>
                </caption>
                <graphic xlink:href="JAH3-10-e019017-g002" position="anchor" id="jats-graphic-3"/>
              </fig>
              <table-wrap position="float" id="jah36206-tbl-0002" content-type="Table">
                <label>Table 2</label>
                <caption>
                  <p>Hazard Ratios and 95% Confidence Intervals From Multivariable Analysis of Mortality</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">Predictor</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">HR [95% CI]</th>
                      <th align="center" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> Value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Beta‐blocker dose</td>
                      <td align="left" rowspan="1" colspan="1">see Figure <xref rid="jah36206-fig-0003" ref-type="fig">3</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Age</td>
                      <td align="left" rowspan="1" colspan="1">1.045 [1.027–1.062]</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">BMI<xref rid="jah36206-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">−0.129±0.032</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">BMI<sup>2</sup>
<xref rid="jah36206-note-0007" ref-type="table-fn">*</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.0017±0.0004</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Hypertension</td>
                      <td align="left" rowspan="1" colspan="1">2.204 [1.215–3.373]</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.007</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">ESRD</td>
                      <td align="left" rowspan="1" colspan="1">3.098 [1.821–5.271]</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">History of CHF</td>
                      <td align="left" rowspan="1" colspan="1">1.826 [1.205–2.766]</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.004</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Primary PCI</td>
                      <td align="left" rowspan="1" colspan="1">0.518 [0.332–0.808]</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.004</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">CABG</td>
                      <td align="left" rowspan="1" colspan="1">1.579 [1.055–2.363]</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.03</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">In‐hospital revascularization</td>
                      <td align="left" rowspan="1" colspan="1">0.585 [0.380–0.902]</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah36206-ntgp-0003">
                  <fn id="jah36206-note-0006">
                    <p>HRs for continuous variables are associated with a 1‐unit increase in the measure. BMI indicates body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; ESRD, end‐stage renal disease; HR, hazard ratio; and PCI, percutaneous coronary intervention.</p>
                  </fn>
                  <fn id="jah36206-note-0007">
                    <label>*</label>
                    <p>Because HR is not constant across the range of BMI, model regression coefficient rather than HR is reported.</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                </permissions>
              </table-wrap>
              <fig position="float" fig-type="Figure" id="jah36206-fig-0003">
                <label>Figure 3</label>
                <caption>
                  <title>Hazard ratios for the multivariable and propensity score analyses for the various beta‐blocker (BB) groups relative to the &gt;12.5% to 25% dose.</title>
                  <p>*<italic toggle="yes">P</italic>&lt;0.08 versus &gt;12.5% to 25% dose. <sup>†</sup>
<italic toggle="yes">P</italic>&lt;0.02 versus &gt;12.5% to 25% dose.</p>
                </caption>
                <graphic xlink:href="JAH3-10-e019017-g001" position="anchor" id="jats-graphic-5"/>
              </fig>
              <p>Among the specified subgroup analyses, only history of congestive heart failure demonstrated significant interaction with beta‐blocker effects on survival. In the binary analysis, only the patients with history of congestive heart failure showed beta‐blocker benefit (HR, 0.442; 95% CI, 0.212–0.920; <italic toggle="yes">P</italic>=0.029), whereas no effect was observed for patients without history of congestive heart failure (HR, 1.232; 95% CI, 0.641–2.366; <italic toggle="yes">P</italic>=0.53; <italic toggle="yes">P</italic>=0.04 for the interaction). The effect remained after multivariable adjustment (<italic toggle="yes">P</italic>=0.014). In the beta‐blocker dose analysis, there was also a significant interaction with beta‐blocker effects on survival (<italic toggle="yes">P</italic>=0.011 for the interaction). In patients with a history of congestive heart failure, mortality was higher for those in all beta‐blocker dose categories except the &gt;25% to 50% dose relative to the &gt;12.5% to 25% dose (not taking beta‐blockers HR, 3.080; 95% CI, 1.141–8.319; <italic toggle="yes">P</italic>=0.027; &gt;0%–12.5% dose HR, 2.727; 95% CI, 1.068–6.963; <italic toggle="yes">P</italic>=0.036; &gt;50–100% dose HR, 1.919; 95% CI, 1.041–3.536; <italic toggle="yes">P</italic>=0.037). In patients without a history of congestive heart failure, only the &gt;25% to 50% dose had inferior outcomes compared with the &gt;12.5% to 25% dose (HR, 2.223; 95% CI, 1.313–3.764; <italic toggle="yes">P</italic>=0.0029). The difference among beta‐blocker effects in this subgroup analysis persisted after multivariable adjustment (<italic toggle="yes">P</italic>=0.030). Beta‐blocker effect was also different in patients with ST‐segment–elevation myocardial infarction versus non–ST‐segment–elevation myocardial infarction (<italic toggle="yes">P</italic>&lt;0.0001); however, this difference was no longer significant after multivariable adjustment (<italic toggle="yes">P</italic>=0.65). None of the other subgroups (patients with left ventricular ejection fraction above or below 40%, patients with in‐hospital revascularization versus without) demonstrated a significant interaction with a beta‐blocker.</p>
            </sec>
            <sec sec-type="discussion" id="jah36206-sec-0013">
              <title>Discussion</title>
              <p>This landmark analysis of the OBTAIN study was designed to evaluate whether there is benefit to beta‐blocker therapy beyond 1 year after MI. When analyzed dichotomously, beta‐blocker therapy beyond 1 year after an MI was not associated with improved survival. However, on the basis of the primary OBTAIN study<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> results, we hypothesized there would be a dose‐dependent effect of beta‐blocker dosing in 1‐year survivors after an acute MI. Both multivariate and propensity score analyses of survival by dose suggested that patients treated with &gt;12.5% to 25% of the target dose have enhanced survival compared with no beta‐blocker therapy and other beta‐blocker doses. The present study provides important data on the role of beta‐blocker dose and therapy in 1‐year survivors after MI.</p>
              <p>CAPRICORN (Carvedilol Post‐Infarct Survival Control in LV Dysfunction)<xref rid="jah36206-bib-0012" ref-type="bibr"><sup>12</sup></xref> is the only reperfusion‐era randomized clinical trial to demonstrate a survival benefit of beta‐blocker therapy; in this trial of carvedilol versus placebo in patients after MI with left ventricular ejection fraction ≤40%, the survival curves continued to diverge for 2.5 years, suggesting long‐term benefit for this low ejection fraction group. Our findings in the subgroup of patients with a history of congestive heart failure support the continued benefit of beta‐blocker therapy in patients after MI with left ventricular dysfunction and/or heart failure. Two recent landmark analyses at 1 year after MI have been reported. In these observational studies of 1383<xref rid="jah36206-bib-0016" ref-type="bibr"><sup>16</sup></xref> and 1946<xref rid="jah36206-bib-0017" ref-type="bibr"><sup>17</sup></xref> patients, there was no benefit to beta‐blocker therapy when analyzed as a dichotomous variable. In a report from the French national health insurance database including 73 450 patients after MI who had been treated with beta‐blockers for at least 1 year, there was no significant increase in mortality associated with beta‐blocker discontinuation (HR, 1.13; 95% CI, 0.94–1.36).<xref rid="jah36206-bib-0018" ref-type="bibr"><sup>18</sup></xref> The dichotomous analysis in this OBTAIN report is consistent with these findings. However, beta‐blocker dose may be an important modulator of beta‐blocker benefit.<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jah36206-bib-0019" ref-type="bibr"><sup>19</sup></xref> It is notable that the same dose (25% of the target dose used in randomized clinical trials) was found to be the optimal dose in this report as in the original OBTAIN report.<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> Furthermore, in this subsample of the OBTAIN study, ≈40% of patients had a change in dose from the discharge dose used in the analysis of the original OBTAIN cohort.<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> The only inconsistent finding in the current analysis is the lack of benefit of the &gt;12.5% to 25% dose relative to the &gt;50% dose. This may relate to this latter group being the smallest of the beta‐blocker treatment groups. In a report from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) registry,<xref rid="jah36206-bib-0020" ref-type="bibr"><sup>20</sup></xref> a landmark analysis was performed at 3 years after MI in patients aged ≥65 years old (mean age, 75 years), stratified by no beta‐blocker, &lt;50% of target dose, and ≥50% of target dose. No difference in outcomes was noted. However, there was no delineation between the 12.5% and 25% dose. Furthermore, the authors note that the findings were consistent in patients with and without heart failure or systolic dysfunction, questioning the generalizability of these findings. Therefore, the present report provides further support that the medical discussion around the use of beta‐blockers after MI, even long‐term use, must center on dose and not simply use. This is a major paradigm change, because the vast majority of studies in this field do not address dose. It is important to note that there has not been a single randomized clinical trial of beta‐blockers after acute MI that tested multiple doses.</p>
              <p>Although the present findings are intriguing, they should be considered exploratory in nature. Beta‐blocker dosing was at the physician's discretion. Although there are no data on the reasons for down‐titration, maintenance of the same dose, or up‐titration Figure <xref rid="jah36206-fig-0001" ref-type="fig">1</xref>, clearly shows the inertial effects of discharge dosing across the spectrum of doses. In real‐world cardiac practice, target doses from clinical trials are often not achieved.<xref rid="jah36206-bib-0021" ref-type="bibr"><sup>21</sup></xref>
</p>
              <p>A variety of mechanisms have been suggested to underlie the improved survival associated with beta‐blocker therapy after MI. These include anti‐ischemic effects, prevention of reinfarction, and reduction in arrhythmic sudden death. In the modern era of reperfusion therapies and aspirin and statin use, the role of beta‐blockers for the first two mechanisms may have substantially diminished. Its role in the prevention of arrhythmic sudden death, however, may still be vital. VALIANT (Valsartan in Acute Myocardial Infarction Trial)<xref rid="jah36206-bib-0022" ref-type="bibr"><sup>22</sup></xref> reported the monthly rate of sudden death after MI. This peaked in the first month after MI and rapidly declined over 6 months. By 12 months, this appeared to plateau. Although the mechanism of sudden death in the early post‐MI period is likely multifactorial,<xref rid="jah36206-bib-0023" ref-type="bibr"><sup>23</sup></xref> an autopsy study suggested that half of the sudden deaths occurring beyond 1 year after acute MI are presumed arrhythmic. Olsson et al.<xref rid="jah36206-bib-0024" ref-type="bibr"><sup>24</sup></xref> demonstrated that metoprolol reduced sudden death substantially following acute MI, with an increasing effect over 3 years. There are no data evaluating the dose response for the protective effect of beta‐blockers against sudden death. In light of the potential detrimental effects of higher doses of beta‐blockers, other approaches for primary prevention may need to be considered. It is interesting to note that primary prevention implantable cardioverter defibrillators following acute MI have not provided any survival benefit over a period of several years.<xref rid="jah36206-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="jah36206-bib-0026" ref-type="bibr"><sup>26</sup></xref>
</p>
              <p>There are potential detrimental effects of higher doses of beta‐blockers. In a compilation of data from randomized clinical trials of beta‐blockers in heart failure,<xref rid="jah36206-bib-0027" ref-type="bibr"><sup>27</sup></xref> significant adverse effects included hypotension and bradycardia. These are both dose dependent. Unappreciated downstream effects can be considered, such as diminished physical activity. It is well known that outcomes post‐MI are improved with increased physical activity.<xref rid="jah36206-bib-0028" ref-type="bibr"><sup>28</sup></xref> Clearly, further research is needed in this area to better identify the individual balance of beneficial and adverse effects that occur across the clinically used dose spectrum.</p>
              <sec id="jah36206-sec-0014">
                <title>Limitations</title>
                <p>The major limitation of the current study is that it is an observational cohort in which there were differences in patient characteristics among the treatment groups. Although these differences were adjusted in multivariable and propensity score analyses and provided consistent results, there may be unrecognized confounders that were not accounted for. The dose‐dependent effects could differ among different beta‐blockers. Yet, this information is the best currently available and provides important impetus to change our paradigm of clinical care and investigation related to beta‐blocker use after MI. Finally, dose was determined at the 1‐year time point and not reassessed; the reasons for dose maintenance or change are also unknown.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah36206-sec-0015">
              <title>Conclusions</title>
              <p>Given the tremendous advances that have been made in the management of acute MI and post‐MI treatments, it is necessary to reconsider the role of beta‐blocker therapy. However, the relevant question is no longer whether all patients with acute MI should be treated with beta‐blockers. The OBTAIN study<xref rid="jah36206-bib-0009" ref-type="bibr"><sup>9</sup></xref> and this substudy support the need for a new paradigm that addresses which patients should be treated, for how long, and at what dose. An important role for personalized medicine in the management of this diverse patient population must be incorporated. Further randomized clinical trials are required to prospectively test dosing and treatment durations for beta‐blocker therapy following acute MI.</p>
            </sec>
            <sec id="jah36206-sec-0016">
              <title>Appendix</title>
              <sec id="jah36206-sec-0017">
                <title>OBTAIN (Outcomes of Beta‐Blocker Therapy After Myocardial Infarction) Investigators</title>
                <p>The following investigators, coordinators, and centers participated in the study: P. Desai, M. Betzen, D. DeLuna, <italic toggle="yes">Amarillo Heart Clinical Research Institute, Amarillo;</italic> J. Whitehill, J. Hatch, L. Janak, R. Cherry, <italic toggle="yes">Austin Heart P.A., Austin;</italic> E. Gonzalez, I. Cruz, <italic toggle="yes">Baptist Cardiac &amp; Vascular Institute, Miami;</italic> E. Johnson, C. Allbritton, V. Derrick, <italic toggle="yes">Baptist Memorial Hospital, Memphis;</italic> R. Fishman, V. Assalone, L. Mahon, <italic toggle="yes">Bridgeport Hospital, Bridgeport;</italic> D. Lustgarten, M. Rowen, M. Bessette, B. Alemy, <italic toggle="yes">Fletcher Allen Health Care, Burlington;</italic> D. Dan, K. Picardi, <italic toggle="yes">Fuqua Heart Center, Atlanta;</italic> C. Schuger, J. Dzidowski, M. McCarthy, P. Fields, S. Alexander, <italic toggle="yes">Henry Ford Hospital, Detroit;</italic> G. Nair, R. Kovacs, D. Beasley, T. Strickland, J. Marks, <italic toggle="yes">IU Health Methodist Research Institute, Indianapolis;</italic> S. Beau, J. Tableriou, B. Griffin, <italic toggle="yes">Little Rock Cardiology Clinic, Little Rock;</italic> J. Shani, M. Stokes‐McCarthy, G. Tan‐Augenstein, G. Pace, H. Brosnan, <italic toggle="yes">Maimonides Medical Center, New York;</italic> J. Hayes, K. Mancl, K. Maassen, <italic toggle="yes">Marshfield Clinic, Marshfield;</italic> D. Fintel, L. Karpf, T. Abraham, K. Campione, E. Martin, <italic toggle="yes">Northwestern Memorial Hospital, Chicago;</italic> D. Bello, I. Viera Fleetwood, M. Tinetti, R. Rock, <italic toggle="yes">Orlando Regional Medical Center, Orlando;</italic> J. Simonson, S. Barnes, J. Letexier, M. Strothman, J. Mattson, <italic toggle="yes">Park Nicollet Institute, Minneapolis;</italic> C. Albert Shoultz III, S. Ali, <italic toggle="yes">Providence Healthcare Network;</italic> D. Abbott, M. Medeiros, J. McKeon, <italic toggle="yes">Rhode Island Hospital/Brown Medical School, Providence;</italic> A. Nichols, T. Edwards, C. Watts, C. Alley, <italic toggle="yes">Riverside Methodist Hospital, Columbus;</italic> M. Romanelli, D. Steffen, R. Henschel, S. Teller, L. Froehlich, R. Bess, <italic toggle="yes">St. John Hospital &amp; Medical Center, Detroit;</italic> W. Warnica, B. Smith, D. Eichman, D. Scarcelli, <italic toggle="yes">University of Calgary, Calgary;</italic> N. Badhwar, P. Malone, D. Green, S. Iyer, <italic toggle="yes">University of California at San Francisco, San Francisco;</italic> R. Germany, C. Murray, G. Straughn, K. Drennan, <italic toggle="yes">University of Oklahoma, Oklahoma City;</italic> O. Marroquin, L. Dennis, C. Farrow, L. Baxendell, S. Grate, M. Enlow, <italic toggle="yes">University of Pittsburgh Medical Center, Pittsburgh;</italic> W. Zareba, I. Chaudhary, P. Laduke, V. Conary‐Rocco, L. Caufield, C. Patterson, <italic toggle="yes">University of Rochester—Strong Memorial Hospital, Rochester;</italic> A. Warner, J. Johnson, <italic toggle="yes">West Los Angeles VA Medical Center, Los Angeles;</italic> J. Germano, W. Drewes, B. George, B. Yoo, D. Patel, <italic toggle="yes">Winthrop University Hospital, Mineola</italic>.</p>
                <sec id="jah36206-sec-0018">
                  <title>Steering Committee</title>
                  <p>R. Bonow*, <italic toggle="yes">Northwestern University, Chicago;</italic> M. Cuffe*, <italic toggle="yes">Hospital Corporation of America;</italic> A. Dyer, <italic toggle="yes">Northwestern University, Chicago;</italic> P. Greenland, <italic toggle="yes">Northwestern University, Chicago</italic> J. Goldberger*, <italic toggle="yes">Northwestern University, Chicago;</italic> R. O’Rourke, <italic toggle="yes">University of Texas Health Science Center at San Antonio, San Antonio;</italic> Y. Rosenberg*, <italic toggle="yes">National Heart, Lung, and Blood Institute, Bethesda;</italic> P. Shah*, <italic toggle="yes">Cedar‐Sinai Medical Center, Los Angeles;</italic> S. Smith*, <italic toggle="yes">University of North Carolina, Chapel Hill</italic>.</p>
                  <p>*Current members (all original members are listed).</p>
                </sec>
                <sec id="jah36206-sec-0019">
                  <title>Observational Study Monitoring Board</title>
                  <p>R. Byington, <italic toggle="yes">Wake Forest University Health Science, Winston‐Salem, N.C.;</italic> Z. Feng, <italic toggle="yes">Fred Hutchinson Cancer Research Center, Seattle;</italic> S. Goldstein, <italic toggle="yes">Henry Ford Hospital, Detroit;</italic> J. Kirkpatrick, <italic toggle="yes">Hospital of the University of Pennsylvania;</italic> C. Love, <italic toggle="yes">New York University Medical Center, New York;</italic> S. Singh, <italic toggle="yes">Veteran Affairs Medical Center, Washington, D.C</italic>.</p>
                </sec>
                <sec id="jah36206-sec-0020">
                  <title>National Heart, Lung, and Blood Institute</title>
                  <p>Y. Rosenberg, S. Goldberg, M. Kwak, A. Rao, P. Srinivas.</p>
                </sec>
                <sec id="jah36206-sec-0021">
                  <title>Northwestern University Clinical and Data Coordinating Center</title>
                  <p>J. Goldberger, C. Ball, J. Cahill, A. Schaechter, D. Alexander, K. Ma, T. Plant, A. Rosenfeld, J. Scofic, J. Simon, H. Subačius.</p>
                </sec>
              </sec>
            </sec>
            <sec id="jah36206-sec-0023">
              <title>Sources of Funding</title>
              <p>This research was supported by grant No. 5U01HL080416 from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the Miami Heart Research Institute.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah36206-sec-0024">
              <title>Disclosures</title>
              <p>None.</p>
            </sec>
          </body>
          <back>
            <ack id="jah36206-sec-0022">
              <title>Acknowledgments</title>
              <p>The authors thank all of the site investigators and research coordinators for their support of this study.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah36206-bibl-0001">
              <title>References</title>
              <ref id="jah36206-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0001"><string-name><surname>Amsterdam</surname><given-names>EA</given-names></string-name>, <string-name><surname>Wenger</surname><given-names>NK</given-names></string-name>, <string-name><surname>Brindis</surname><given-names>RG</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Ganiats</surname><given-names>TG</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Jaffe</surname><given-names>AS</given-names></string-name>, <string-name><surname>Jneid</surname><given-names>H</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>RF</given-names></string-name>, <string-name><surname>Kontos</surname><given-names>MC</given-names></string-name>, et al. <article-title>2014 AHA/ACC guideline for the management of patients with non‐ST‐elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>:<fpage>e344</fpage>–<lpage>e426</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000134</pub-id>.<pub-id pub-id-type="pmid">25249585</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0002"><string-name><surname>O’Gara</surname><given-names>PT</given-names></string-name>, <string-name><surname>Kushner</surname><given-names>FG</given-names></string-name>, <string-name><surname>Ascheim</surname><given-names>DD</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names></string-name>, <string-name><surname>Chung</surname><given-names>MK</given-names></string-name>, <string-name><surname>de Lemos</surname><given-names>JA</given-names></string-name>, <string-name><surname>Ettinger</surname><given-names>SM</given-names></string-name>, <string-name><surname>Fang</surname><given-names>JC</given-names></string-name>, <string-name><surname>Fesmire</surname><given-names>FM</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>BA</given-names></string-name>, et al. <article-title>2013 ACCF/AHA guideline for the management of ST‐elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>127</volume>:<fpage>529</fpage>–<lpage>555</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIR.0b013e3182742c84</pub-id>.<pub-id pub-id-type="pmid">23247303</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0003"><string-name><surname>Ibanez</surname><given-names>B</given-names></string-name>, <string-name><surname>James</surname><given-names>S</given-names></string-name>, <string-name><surname>Agewall</surname><given-names>S</given-names></string-name>, <string-name><surname>Antunes</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bucciarelli‐Ducci</surname><given-names>C</given-names></string-name>, <string-name><surname>Bueno</surname><given-names>H</given-names></string-name>, <string-name><surname>Caforio</surname><given-names>ALP</given-names></string-name>, <string-name><surname>Crea</surname><given-names>F</given-names></string-name>, <string-name><surname>Goudevenos</surname><given-names>JA</given-names></string-name>, <string-name><surname>Halvorsen</surname><given-names>S</given-names></string-name>, et al. <article-title>2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST‐segment elevation of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source>. <year>2018</year>;<volume>39</volume>:<fpage>119</fpage>–<lpage>177</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id>.<pub-id pub-id-type="pmid">28886621</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0004"><string-name><surname>Roffi</surname><given-names>M</given-names></string-name>, <string-name><surname>Patrono</surname><given-names>C</given-names></string-name>, <string-name><surname>Collet</surname><given-names>J‐P</given-names></string-name>, <string-name><surname>Mueller</surname><given-names>C</given-names></string-name>, <string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name><surname>Andreotti</surname><given-names>F</given-names></string-name>, <string-name><surname>Bax</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Borger</surname><given-names>MA</given-names></string-name>, <string-name><surname>Brotons</surname><given-names>C</given-names></string-name>, <string-name><surname>Chew</surname><given-names>DP</given-names></string-name>, et al. <article-title>2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST‐Segment Elevation of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>:<fpage>267</fpage>–<lpage>315</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurheartj/ehv320</pub-id>.<pub-id pub-id-type="pmid">26320110</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0005"><string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Bonow</surname><given-names>RO</given-names></string-name>, <string-name><surname>Braun</surname><given-names>LT</given-names></string-name>, <string-name><surname>Creager</surname><given-names>MA</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>BA</given-names></string-name>, <string-name><surname>Gibbons</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Grundy</surname><given-names>SM</given-names></string-name>, <string-name><surname>Hiratzka</surname><given-names>LF</given-names></string-name>, <string-name><surname>Jones</surname><given-names>DW</given-names></string-name>, et al. <article-title>AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>2458</fpage>–<lpage>2473</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIR.0b013e318235eb4d</pub-id>.<pub-id pub-id-type="pmid">22052934</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0006"><string-name><surname>Bangalore</surname><given-names>S</given-names></string-name>, <string-name><surname>Makani</surname><given-names>H</given-names></string-name>, <string-name><surname>Radford</surname><given-names>M</given-names></string-name>, <string-name><surname>Thakur</surname><given-names>K</given-names></string-name>, <string-name><surname>Toklu</surname><given-names>B</given-names></string-name>, <string-name><surname>Katz</surname><given-names>SD</given-names></string-name>, <string-name><surname>DiNicolantonio</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Devereaux</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name><surname>Wetterslev</surname><given-names>J</given-names></string-name>, et al. <article-title>Clinical outcomes with β‐blockers for myocardial infarction: a meta‐analysis of randomized trials</article-title>. <source>Am J Med</source>. <year>2014</year>;<volume>127</volume>:<fpage>939</fpage>–<lpage>953</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.amjmed.2014.05.032</pub-id>.<pub-id pub-id-type="pmid">24927909</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0007"><string-name><surname>Chen</surname><given-names>ZM</given-names></string-name>, <string-name><surname>Pan</surname><given-names>HC</given-names></string-name>, <string-name><surname>Chen</surname><given-names>YP</given-names></string-name>, <string-name><surname>Peto</surname><given-names>R</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>LX</given-names></string-name>, <string-name><surname>Xie</surname><given-names>JX</given-names></string-name>, <string-name><surname>Liu</surname><given-names>LS</given-names></string-name>. <article-title>Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>366</volume>:<fpage>1622</fpage>–<lpage>1632</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67661-1</pub-id>.<pub-id pub-id-type="pmid">16271643</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0008"><string-name><surname>Pedersen</surname><given-names>TR</given-names></string-name>. <article-title>Six‐year follow‐up of the Norwegian multicenter study on timolol after acute myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1985</year>;<volume>313</volume>:<fpage>1055</fpage>–<lpage>1058</lpage>.<pub-id pub-id-type="pmid">2864634</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0009"><string-name><surname>Goldberger</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Bonow</surname><given-names>RO</given-names></string-name>, <string-name><surname>Cuffe</surname><given-names>M</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shah</surname><given-names>PK</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Subacius</surname><given-names>H</given-names></string-name>; <collab collab-type="authors">Investigators O</collab>
. <article-title>Effect of beta‐blocker dose on survival after acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>:<fpage>1431</fpage>–<lpage>1441</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2015.07.047</pub-id>.<pub-id pub-id-type="pmid">26403339</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0010"><collab collab-type="authors">The MIAMI Trial Research Group</collab>
. <article-title>Metroprolol in acute myocardial infarction (MIAMI): a randomized placebo‐controlled international trial</article-title>. <source>Eur Heart J</source>. <year>1985</year>;<volume>6</volume>:<fpage>199</fpage>–<lpage>226</lpage>.<pub-id pub-id-type="pmid">2863148</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0011"><string-name><surname>Hjalmarson</surname><given-names>Å</given-names></string-name>, <string-name><surname>Herlitz</surname><given-names>J</given-names></string-name>, <string-name><surname>Málek</surname><given-names>I</given-names></string-name>, <string-name><surname>Rydén</surname><given-names>L</given-names></string-name>, <string-name><surname>Vedin</surname><given-names>A</given-names></string-name>, <string-name><surname>Waldenström</surname><given-names>A</given-names></string-name>, <string-name><surname>Wedel</surname><given-names>H</given-names></string-name>, <string-name><surname>Elmfeldt</surname><given-names>D</given-names></string-name>, <string-name><surname>Holmberg</surname><given-names>S</given-names></string-name>, <string-name><surname>Nyberg</surname><given-names>G</given-names></string-name>, et al. <article-title>Effect on mortality of metoprolol in acute myocardial infarction: a double‐blind randomized trial</article-title>. <source>Lancet</source>. <year>1981</year>;<volume>2</volume>:<fpage>823</fpage>–<lpage>827</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/S0140-6736(81)91101-6</pub-id>.<pub-id pub-id-type="pmid">6116950</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0012"><string-name><surname>Dargie</surname><given-names>HJ</given-names></string-name>. <article-title>Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: the CAPRICORN randomised trial</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>357</volume>:<fpage>1385</fpage>–<lpage>1390</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/s0140-6736(00)04560-8</pub-id>.<pub-id pub-id-type="pmid">11356434</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0013"><article-title>A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results</article-title>. <source>JAMA</source>. <year>1982</year>;<volume>247</volume>:<fpage>1707</fpage>–<lpage>1714</lpage>.<pub-id pub-id-type="pmid">7038157</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0014"><collab collab-type="authors">CIBIS‐II Investigators and Committees</collab>
. <article-title>The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>353</volume>:<fpage>9</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">10023943</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0015"><string-name><surname>Viskin</surname><given-names>S</given-names></string-name>, <string-name><surname>Kitzis</surname><given-names>I</given-names></string-name>, <string-name><surname>Lev</surname><given-names>E</given-names></string-name>, <string-name><surname>Zak</surname><given-names>Z</given-names></string-name>, <string-name><surname>Heller</surname><given-names>K</given-names></string-name>, <string-name><surname>Villa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zajarias</surname><given-names>A</given-names></string-name>, <string-name><surname>Laniado</surname><given-names>S</given-names></string-name>, <string-name><surname>Belhassen</surname><given-names>B</given-names></string-name>. <article-title>Treatment with beta‐adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice</article-title>. <source>J Am Coll Cardiol</source>. <year>1995</year>;<volume>25</volume>:<fpage>1327</fpage>–<lpage>1332</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/0735-1097(94)00552-2</pub-id>.<pub-id pub-id-type="pmid">7722129</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0016"><string-name><surname>Puymirat</surname><given-names>E</given-names></string-name>, <string-name><surname>Riant</surname><given-names>E</given-names></string-name>, <string-name><surname>Aissaoui</surname><given-names>N</given-names></string-name>, <string-name><surname>Soria</surname><given-names>A</given-names></string-name>, <string-name><surname>Ducrocq</surname><given-names>G</given-names></string-name>, <string-name><surname>Coste</surname><given-names>P</given-names></string-name>, <string-name><surname>Cottin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Aupetit</surname><given-names>JF</given-names></string-name>, <string-name><surname>Bonnefoy</surname><given-names>E</given-names></string-name>, <string-name><surname>Blanchard</surname><given-names>D</given-names></string-name>, et al. <article-title>β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study</article-title>. <source>BMJ</source>. <year>2016</year>;<volume>354</volume>:<fpage>i4801</fpage>. DOI: <pub-id pub-id-type="doi">10.1136/bmj.i4801</pub-id>.<pub-id pub-id-type="pmid">27650822</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0017"><string-name><surname>Park</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name><surname>Kang</surname><given-names>SH</given-names></string-name>, <string-name><surname>Yoon</surname><given-names>CH</given-names></string-name>, <string-name><surname>Cho</surname><given-names>YS</given-names></string-name>, <string-name><surname>Youn</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Chae</surname><given-names>IH</given-names></string-name>, <string-name><surname>Choi</surname><given-names>DJ</given-names></string-name>. <article-title>Effect of beta‐blockers beyond 3 years after acute myocardial infarction</article-title>. <source>J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>:<elocation-id>e007567</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.117.007567</pub-id>.<pub-id pub-id-type="pmid">29502101</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0018"><string-name><surname>Neumann</surname><given-names>A</given-names></string-name>, <string-name><surname>Maura</surname><given-names>G</given-names></string-name>, <string-name><surname>Weill</surname><given-names>A</given-names></string-name>, <string-name><surname>Alla</surname><given-names>F</given-names></string-name>, <string-name><surname>Danchin</surname><given-names>N</given-names></string-name>. <article-title>Clinical events after discontinuation of β‐blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French healthcare databases</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2018</year>;<volume>11</volume>:<elocation-id>e004356</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.117.004356</pub-id>.<pub-id pub-id-type="pmid">29653999</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0019"><string-name><surname>Allen</surname><given-names>JE</given-names></string-name>, <string-name><surname>Knight</surname><given-names>S</given-names></string-name>, <string-name><surname>McCubrey</surname><given-names>RO</given-names></string-name>, <string-name><surname>Bair</surname><given-names>T</given-names></string-name>, <string-name><surname>Muhlestein</surname><given-names>JB</given-names></string-name>, <string-name><surname>Goldberger</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>JL</given-names></string-name>. <article-title>β‐blocker dosage and outcomes after acute coronary syndrome</article-title>. <source>Am Heart J</source>. <year>2017</year>;<volume>184</volume>:<fpage>26</fpage>–<lpage>36</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.ahj.2016.10.012</pub-id>.<pub-id pub-id-type="pmid">27892884</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0020"><string-name><surname>Shavadia</surname><given-names>JS</given-names></string-name>, <string-name><surname>Holmes</surname><given-names>DN</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>L</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>ED</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name><surname>Wang</surname><given-names>TY</given-names></string-name>. <article-title>Comparative effectiveness of beta‐blocker use beyond 3 years after myocardial infarction and long‐term outcomes among elderly patients</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2019</year>;<volume>12</volume>:<elocation-id>e005103</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.118.005103</pub-id>.<pub-id pub-id-type="pmid">31284739</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0021"><string-name><surname>Maggioni</surname><given-names>AP</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name><surname>Dahlström</surname><given-names>U</given-names></string-name>, <string-name><surname>Filippatos</surname><given-names>G</given-names></string-name>, <string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>Amir</surname><given-names>O</given-names></string-name>, <string-name><surname>Chioncel</surname><given-names>O</given-names></string-name>, <string-name><surname>Leiro</surname><given-names>MC</given-names></string-name>, <string-name><surname>Drozdz</surname><given-names>J</given-names></string-name>, et al. <article-title>Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long‐Term Registry</article-title>. <source>Eur J Heart Fail</source>. <year>2013</year>;<volume>15</volume>:<fpage>1173</fpage>–<lpage>1184</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurjhf/hft134</pub-id>.<pub-id pub-id-type="pmid">23978433</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0022"><string-name><surname>Solomon</surname><given-names>SD</given-names></string-name>, <string-name><surname>Zelenkofske</surname><given-names>S</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJV</given-names></string-name>, <string-name><surname>Finn</surname><given-names>PV</given-names></string-name>, <string-name><surname>Velazquez</surname><given-names>E</given-names></string-name>, <string-name><surname>Ertl</surname><given-names>G</given-names></string-name>, <string-name><surname>Harsanyi</surname><given-names>A</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>JL</given-names></string-name>, <string-name><surname>Maggioni</surname><given-names>A</given-names></string-name>, <string-name><surname>Kober</surname><given-names>L</given-names></string-name>, et al. <article-title>Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>352</volume>:<fpage>2581</fpage>–<lpage>2588</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa043938</pub-id>.<pub-id pub-id-type="pmid">15972864</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0023"><string-name><surname>Pouleur</surname><given-names>A‐C</given-names></string-name>, <string-name><surname>Barkoudah</surname><given-names>E</given-names></string-name>, <string-name><surname>Uno</surname><given-names>H</given-names></string-name>, <string-name><surname>Skali</surname><given-names>H</given-names></string-name>, <string-name><surname>Finn</surname><given-names>PV</given-names></string-name>, <string-name><surname>Zelenkofske</surname><given-names>SL</given-names></string-name>, <string-name><surname>Belenkov</surname><given-names>YN</given-names></string-name>, <string-name><surname>Mareev</surname><given-names>V</given-names></string-name>, <string-name><surname>Velazquez</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>JL</given-names></string-name>, et al. <article-title>Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>122</volume>:<fpage>597</fpage>–<lpage>602</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.940619</pub-id>.<pub-id pub-id-type="pmid">20660803</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0024"><string-name><surname>Olsson</surname><given-names>G</given-names></string-name>, <string-name><surname>Rehnqvist</surname><given-names>N</given-names></string-name>, <string-name><surname>Sjogren</surname><given-names>A</given-names></string-name>, <string-name><surname>Erhardt</surname><given-names>L</given-names></string-name>, <string-name><surname>Lundman</surname><given-names>T</given-names></string-name>. <article-title>Long‐term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity</article-title>. <source>J Am Coll Cardiol</source>. <year>1985</year>;<volume>5</volume>:<fpage>1428</fpage>–<lpage>1437</lpage>.<pub-id pub-id-type="pmid">3889100</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0025"><string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name><surname>Kuck</surname><given-names>KH</given-names></string-name>, <string-name><surname>Dorian</surname><given-names>P</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>RS</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>JR</given-names></string-name>, <string-name><surname>Hatala</surname><given-names>R</given-names></string-name>, <string-name><surname>Fain</surname><given-names>E</given-names></string-name>, <string-name><surname>Gent</surname><given-names>M</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name>. <article-title>Prophylactic use of an implantable cardioverter‐defibrillator after acute myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>:<fpage>2481</fpage>–<lpage>2488</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa041489</pub-id>.<pub-id pub-id-type="pmid">15590950</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0026"><string-name><surname>Steinbeck</surname><given-names>G</given-names></string-name>, <string-name><surname>Andresen</surname><given-names>D</given-names></string-name>, <string-name><surname>Seidl</surname><given-names>K</given-names></string-name>, <string-name><surname>Brachmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Hoffmann</surname><given-names>E</given-names></string-name>, <string-name><surname>Wojciechowski</surname><given-names>D</given-names></string-name>, <string-name><surname>Kornacewicz‐Jach</surname><given-names>Z</given-names></string-name>, <string-name><surname>Sredniawa</surname><given-names>B</given-names></string-name>, <string-name><surname>Lupkovics</surname><given-names>G</given-names></string-name>, <string-name><surname>Hofgärtner</surname><given-names>F</given-names></string-name>, et al. <article-title>Defibrillator implantation early after myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>1427</fpage>–<lpage>1436</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa0901889</pub-id>.<pub-id pub-id-type="pmid">19812399</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0027"><string-name><surname>Ko</surname><given-names>DT</given-names></string-name>, <string-name><surname>Hebert</surname><given-names>PR</given-names></string-name>, <string-name><surname>Coffey</surname><given-names>CS</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, <string-name><surname>Foody</surname><given-names>JM</given-names></string-name>, <string-name><surname>Sedrakyan</surname><given-names>A</given-names></string-name>, <string-name><surname>Krumholz</surname><given-names>HM</given-names></string-name>. <article-title>Adverse effects of beta‐blocker therapy for patients with heart failure: a quantitative overview of randomized trials</article-title>. <source>Arch Intern Med</source>. <year>2004</year>;<volume>164</volume>:<fpage>1389</fpage>–<lpage>1394</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/archinte.164.13.1389</pub-id>.<pub-id pub-id-type="pmid">15249347</pub-id></mixed-citation>
              </ref>
              <ref id="jah36206-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah36206-cit-0028"><string-name><surname>Ekblom</surname><given-names>O</given-names></string-name>, <string-name><surname>Ek</surname><given-names>A</given-names></string-name>, <string-name><surname>Cider</surname><given-names>A</given-names></string-name>, <string-name><surname>Hambraeus</surname><given-names>K</given-names></string-name>, <string-name><surname>Borjesson</surname><given-names>M</given-names></string-name>. <article-title>Increased physical activity post‐myocardial infarction is related to reduced mortality: results from the SWEDEHEART Registry</article-title>. <source>J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>:<elocation-id>e010108</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.118.010108</pub-id>.<pub-id pub-id-type="pmid">30561263</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
